Maines, Timothy,Machielse, Bernardus N M,Mehta, Bharat M.,Wisler, Gerald,Davidson, Michael,Wood, Peter Ralph
申请号：
NZ73223513
公开号：
NZ732235A
申请日:
2013.01.04
申请国别(地区):
NZ
年份:
2018
代理人:
摘要：
The specification and claims are directed to the composition known in the art as Epanova®. Epanova® comprises eicosapentaenoic acid (“EPA”), in a weight percent amount of 50% to 60% docosahexaenoic acid (“DHA”) in a weight percent amount of 17% to 23% and docosapentaenoic acid (n-3) (“DPA”) (clupanodonic acid) in a weight percent amount of 1% to 8% and wherein at least 90% by weight of the polyunsaturated acid in the composition is present in the free acid form. In a preferred embodiment Epanova® is to be presented in the form of capsule for oral administration of a Type A porcine soft gelatin capsule coated with poly(acrylatemethylmethacrylate) copolymer (Eudragit NE 30-D), and containing one gram of a PUFA composition in which the polyunsaturated fatty acids are present in the form of free fatty acids and contains: 0.55% linoleic acid 0.15% gamma-linolenic acid 0.39% alpha-linolenic acid 1.70% moroctic acid 0.10% eicosadienoic acid 0.35% dihomo-gamma-linolenic acid 2.43% arachidonic acid 0.15% eicosatrienoic acid 2.18% eicosatetraenoic acid 57.25% eicosapentaenoic acid (EPA) 2.79% heneicosapentaenoic acid 0.83% docosapentaenoic acid 6.23% docosapentaenoic acid (DPA) and 19.58% docosahexaenoic acid (DHA). Also disclosed is Epanova® for use in the treatment of severe hypertriglyceridemia, wherein the treatment comprises: orally administering the composition to a patient having pre-treatment serum or plasma triglyceride levels ≥500 mg/dL, in an amount and for a duration effective to reduce serum or plasma triglycerides below pre-treatment levels.
